Clicky

Philogen SpA(PHIL)

Description: Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.


Keywords: Medicine Biotechnology Clinical Medicine Organ Systems Solid Tumors Monoclonal Antibodies Cancer Immunotherapy Non Small Cell Lung Cancer Melanoma Advanced Solid Tumors Treatment Of Non Small Cell Lung Cancer Soft Tissue Sarcoma Metastatic Solid Tumors Glioma Chronic Inflammation Interleukins Transgene Sa Chronic Inflammatory Diseases Non Melanoma Skin Cancers Anti Inflammatory Product

Home Page: www.philogen.com

Via Bellaria, 35
Sovicille, SI 53018
Italy
Phone: 39 0577 17816


Officers

Name Title
Mr. Duccio Neri Co-Founder & Exec. Chairman
Prof. Dario Neri Ph.D. Co-Founder, CEO , CSO, Pres of the Scientific Advisory Board & Director
Mr. Giovanni Neri Co-Founder, Head of IP & Licensing and Director
Ms. Laura Baldi Chief Financial Officer
Dr. Alfredo Covelli M.D. Chief Medical Officer
Dr. Katia Lorizzo Deputy CMO & Head of Clinical Operations

Exchange: MI

Country: IT : Italy

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.4358
Price-to-Sales TTM: 24.355
IPO Date:
Fiscal Year End: December
Full Time Employees: 140
Back to stocks